Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
There have been many reports of the association between migraine headaches and psychiatric disorders as well as of the utility of dopamine antagonists in the treatment of migraine headache. There is increasing evidence to support the activation of dopaminergic systems as a primary component of
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Aripiprazole, a dopamine D2 receptor partial agonist, has been used to treat schizophrenia and might be effective for alcohol dependence and craving. We treated a 53-year-old woman with refractory medication overuse headache, which was successfully treated with aripiprazole. Our experience suggests
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Aripiprazole is widely used in the management of tic disorders (TDs), we aimed to assess the safety of aripiprazole for TDs in children and adolescents.A systematic literature review was performed in the databases of MEDLINE, Embase, the Cochrane Library
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
This systematic review assesses the effectiveness and safety of aripiprazole for treating attention deficit hyperactivity disorder (ADHD). The databases of PubMed/MEDLINE and Google Scholar were searched. All the controlled and non-controlled trials of aripiprazole for the treatment of ADHD were
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
OBJECTIVE
To assess the efficacy and safety of aripiprazole once-monthly 400 mg (AOM 400), an extended-release injectable suspension of aripiprazole, in obese and nonobese patients.
METHODS
This post hoc analysis of a 38-week randomized, double-blind, active-controlled, noninferiority study
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND
This study followed manic or mixed bipolar I subjects for an additional 40 weeks after initial randomization to 12 weeks of lithium versus aripiprazole monotherapy. This is the only long-term, double-blind study comparing lithium and aripiprazole.
METHODS
Patients continued receiving
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The aim of this study was to evaluate the safety and tolerability of aripiprazole once-monthly (ARI-OM) for the maintenance treatment of schizophrenia. This long-term, pivotal study had four phases: oral conversion (phase 1, 4-6 weeks); oral stabilization (phase 2, 4-12 weeks); ARI-OM stabilization
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
OBJECTIVE
To characterize the clinical effects of acute isolated aripiprazole poisonings and to assess the toxic dose of this drug.
METHODS
All isolated acute aripiprazole exposures reported to a poison control system from January 2002 through September 2006 were retrospectively reviewed. Patients
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
OBJECTIVE
To examine the effectiveness and cognitive effects of aripiprazole (APZ) in children with a primary diagnosis of attention-deficit/hyperactivity disorder (ADHD).
METHODS
Youths, ages 8-12 years, with a diagnosis of ADHD combined-type or ADHD predominately inattentive-type were enrolled
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
OBJECTIVE
The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology.
METHODS
Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified,
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Information is available on aripiprazole as a treatment for borderline personality disorder (BPD), but no data have yet been presented concerning the use of this drug as an adjunctive treatment for drug-resistant BPD patients. This study investigates aripiprazole augmentation of ongoing sertraline
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
OBJECTIVE
This study aimed to investigate the efficacy and tolerability of aripiprazole, an atypical antipsychotic with dual agonist and antagonist actions toward dopaminergic imbalance and partial serotonin-2A receptor antagonism, for treating children and adolescents with tic
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of aripiprazole are discussed. Aripiprazole is a third-generation antipsychotic agent indicated for use in the treatment of schizophrenia. Unlike other antipsychotics,
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Aripiprazole is a third generation atypical antipsychotic with compelling evidence as a highly effective treatment option in the management of acute manic and mixed episodes of bipolar I disorders. It has a unique mode of action, acting as a partial agonist at dopamine D2 and D3, and serotonin
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
OBJECTIVE
Aripiprazole,a synthetic compound, obtained by chemical modification of the structure of quinolinone is considered as an atypical antipsychotic drug. The present review is an attempt to summarize the updated information related to reported chemistry and pharmacology of
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont. * Tout enfòmasyon baze sou rechèch syantifik pibliye